USA Financial Formulas Invests $336,000 in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

USA Financial Formulas acquired a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,710 shares of the specialty pharmaceutical company's stock, valued at approximately $336,000.

Other institutional investors have also modified their holdings of the company. Fuller & Thaler Asset Management Inc. increased its position in Jazz Pharmaceuticals by 117.4% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 939,351 shares of the specialty pharmaceutical company's stock worth $115,681,000 after purchasing an additional 507,234 shares during the last quarter. Darwin Global Management Ltd. acquired a new position in Jazz Pharmaceuticals during the fourth quarter worth approximately $59,668,000. Dimensional Fund Advisors LP increased its position in shares of Jazz Pharmaceuticals by 18.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock worth $250,619,000 after acquiring an additional 320,724 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of Jazz Pharmaceuticals by 20.9% in the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock worth $225,076,000 after acquiring an additional 315,608 shares in the last quarter. Finally, GMT Capital Corp increased its position in shares of Jazz Pharmaceuticals by 140.0% in the fourth quarter. GMT Capital Corp now owns 508,800 shares of the specialty pharmaceutical company's stock worth $62,659,000 after acquiring an additional 296,800 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Stock Down 1.6%

Shares of JAZZ stock traded down $1.79 on Friday, hitting $108.50. The stock had a trading volume of 478,127 shares, compared to its average volume of 834,460. Jazz Pharmaceuticals plc has a 52-week low of $95.49 and a 52-week high of $148.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm has a market capitalization of $6.69 billion, a price-to-earnings ratio of 15.28, a P/E/G ratio of 1.04 and a beta of 0.33. The stock's 50 day moving average is $107.84 and its 200-day moving average is $120.54.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The company had revenue of $897.84 million for the quarter, compared to the consensus estimate of $984.16 million. During the same quarter last year, the company earned $2.68 earnings per share. The company's revenue was down .5% compared to the same quarter last year. As a group, research analysts expect that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the firm's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total value of $185,625.00. Following the transaction, the chief executive officer now directly owns 440,307 shares in the company, valued at approximately $54,487,991.25. This trade represents a 0.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Seamus Mulligan purchased 100,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, May 9th. The stock was acquired at an average price of $98.26 per share, for a total transaction of $9,826,000.00. Following the completion of the transaction, the director now owns 100,000 shares in the company, valued at approximately $9,826,000. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders have sold 3,000 shares of company stock worth $355,925 in the last ninety days. 4.20% of the stock is owned by insiders.

Analysts Set New Price Targets

JAZZ has been the subject of several recent research reports. JPMorgan Chase & Co. increased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Piper Sandler reissued an "overweight" rating and issued a $147.00 price objective (down previously from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Barclays reissued an "overweight" rating and issued a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. UBS Group raised shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $145.00 to $179.00 in a research report on Friday, March 7th. Finally, Cantor Fitzgerald lowered shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and increased their price objective for the stock from $140.00 to $150.00 in a research report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $184.00.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.